Q2 2026 Praxis Precision Medicines Inc Earnings Call Transcript
Key Points
- Praxis Precision Medicines Inc (PRAX) received positive feedback from the FDA during mid-cycle reviews for both ulixacaltamide and relutrigine, with no efficacy-related significant issues identified and no Advisory Committee meetings planned for either drug.
- The company successfully completed comprehensive FDA BIMO inspections for both ulixacaltamide and relutrigine applications without any findings or Form 483 issued, validating data integrity and operational procedures.
- Praxis Precision Medicines Inc (PRAX) is well-capitalized with $1.4 billion in cash, providing a runway into 2028 and enabling full commercial launch preparation for both upcoming product approvals.
- The company has made significant commercial progress, including hiring and training a field force for the relutrigine launch and building a comprehensive patient support program and distribution network for both products.
- Praxis Precision Medicines Inc (PRAX) received a third Breakthrough Therapy Designation for elsunersen, highlighting the strength of its pipeline across multiple platforms and assets.
- The EMERALD study for relutrigine exceeded its enrollment target with approximately 200 patients, including over 50 distinct genetic etiologies, positioning the company for a potential supplemental NDA filing in 2027.
- Management expressed confidence in the vormatrigine program, attributing the POWER1 miss to fixable design and dosing issues, with plans to amend and restart POWER2 and POWER3 by Q4 2026.
- Praxis Precision Medicines Inc (PRAX) reported a significant increase in operating expenses, with Q2 2026 operating expenses reaching $96.9 million compared to $76 million in the same period of 2025.
- The company's vormatrigine program failed to meet its primary endpoint in the POWER1 study for focal onset seizures, representing a major clinical setback for that asset.
- The FDA deemed the additional sensitivity analysis submitted for relutrigine a major amendment, extending the review period and pushing the new PDUFA date to December 2027.
- Praxis Precision Medicines Inc (PRAX) faces potential tolerability issues with ulixacaltamide, as approximately 30% of patients may experience initial side effects that could impact patient persistence and commercial uptake.
- The company has chosen to cease providing regulatory updates until the expected action dates, creating a period of uncertainty for investors regarding the approval timelines for both ulixacaltamide and relutrigine.
- Management acknowledged that the vormatrigine program represents only a small fraction of the company's external value, indicating limited near-term upside from this asset.
- The company's cash burn increased significantly, with operating cash spend of $78 million in Q2 2026 compared to $55 million in Q2 2025, reflecting higher costs associated with launch preparations.
Good day and thank you for standing by. Welcome to the Praxis Precision Medicine second quarter 2026 financial results conference call.
(Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to our first speaker today, Daniel Ferry, Managing Director of LifeSci Advisors. Daniel, please go ahead.
Good morning and welcome to the Praxis Precision Medicine's second quarter 2026 financial results and business update Conference Call. This call is being webcast live and can be accessed on the Investors section of Praxis' website at www.praxismedicines.com.
Please note that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about the company's future expectations and plans, clinical development timelines, and financial projections
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
